Advocacy Groups Praise PTO Post-Myriad Guide Amid Industry Criticism

A coalition of international biotechnology groups recently warned that the U.S. Patent and Trademark Office's draft guidance on determining patent eligibility for natural products could have detrimental effects on efforts to harmonize global intellectual property law, and would be harmful to the development of antibiotics and biomarkers used to develop personalized therapies. Pharmaceutical Research and Manufacturers of America charged that PTO is going beyond the scope of its power and Supreme Court precedent, and several companies and industry attorneys reiterated...